Cardiogenic Shock: Treatment

Medical Clinics of North America

Volumn 91, Issue 4, 2007, Pages 713-727

  Iakobishvili, Zaza ^a,b   Hasdai, David ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARGININE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE DERIVATIVE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENIPORIDE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; N(G) METHYLARGININE; NORADRENALIN; PEXELIZUMAB; PLACEBO; REVIPARIN; SODIUM PROTON EXCHANGE PROTEIN; STREPTOKINASE; SUPEROXIDE DISMUTASE; TILARGININE ACETATE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AORTA BALLOON; ARTIFICIAL VENTILATION; BLOOD CLOT LYSIS; BLOOD PRESSURE MONITORING; BYPASS SURGERY; CARDIOGENIC SHOCK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LOW DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; ST SEGMENT ELEVATION; STENT; SURGICAL TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR AGENTS; COUNTERPULSATION; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HUMANS; MYOCARDIAL REVASCULARIZATION; SHOCK, CARDIOGENIC;

EID: 34447309045     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.02.007     Document Type: Review

References (72)

1. Connors A.F.J., Speroff T., Dawson N.V., et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT investigators. JAMA 276 (1996) 889-897
2. Hasdai D., Holmes Jr. D.R., Califf R.M., et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. Am Heart J 138 (1999) 21-31
3. Menon V., Sleeper L.A., Fincke R., et al. Outcomes with pulmonary artery catheterization in cardiogenic shock. [abstract]. J Am Coll Cardiol 31 Suppl A (1998) 397A
4. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004) 671-719
5. Van de Werf F., Ardissino D., Betriu A., et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Aacute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24 (2003) 28-66
6. Porter A., Iakobishvili Z., Haim M., et al. Balloon-floating right heart catheter monitoring for acute coronary syndromes complicated by heart failure-discordance between guidelines and reality. Cardiology 104 (2005) 186-190
7. Hasdai D., Lev E.I., Behar S., et al. Acute coronary syndromes in patients with pre-existing moderate to severe valvular disease of the heart: lessons from the Euro-Heart Survey of Acute Coronary Syndromes. Eur Heart J 24 (2003) 623-629
8. Picard M.H., Davidoff R., Sleeper L.A., et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 107 (2003) 279-284
9. LeDoux D., Astiz M.E., Carpati C.M., et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 28 (2000) 2729-2732
10. Denton M.D., Chertow G.M., and Brady H.R. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 50 (1996) 4-14
11. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet 356 (2000) 2139-2143
12. Juste R.N., Moran L., Hooper J., et al. Dopamine clearance in critically ill patients. Intensive Care Med 24 (1998) 1217-1220
13. Colucci W.S., Denniss A.R., Leatherman G.F., et al. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure: dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. J Clin Invest 81 (1988) 1103-1110
14. Haikala H., Kaheinen P., Levijoki J., et al. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 34 (1997) 536-546
15. Figgitt D.P., Gillies P.S., and Goa K.L. Levosimendan. Drugs 61 (2001) 613-627
16. Lilleberg J., Nieminen M.S., Akkila J., et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19 (1998) 660-668
17. Cleland J.G., and McGowan J. Levosimendan: a new era for inodilator therapy for heart failure?. Curr Opin Cardiol 17 (2002) 257-265
18. Ellger B.M., Zahn P.K., Van Aken H.K., et al. Levosimendan: a promising treatment for myocardial stunning?. Anaesthesia 61 (2006) 61-63
19. Holmes C.L., Walley K.R., Chittock D.R., et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27 (2001) 1416-1421
20. Jolly S., Newton G., Horlock E., et al. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 96 (2005) 1617-1620
21. Bengtson J.R., Kaplan A.J., Pieper K.S., et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 20 (1992) 1482-1489
22. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 8585 (1988) 545-549
23. Wilcox R.G., von der Lippe G., Olsson C.G., et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 8585 (1988) 525-530
24. Hasdai D., Holmes Jr. D.R., Topol E.J., et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase: results from GUSTO III. Eur Heart J 20 (1999) 128-135
25. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 8478 (1986) 397-402
26. Hochman J.S., Sleeper L.A., White H.D., et al. One-year survival following early revascularization for cardiogenic shock. JAMA 285 (2001) 190-192
27. Sanborn T.A., Sleeper L.A., Bates E.R., et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 36 (2000) 1123-1129
28. Prewitt R.M., Gu S., Schick U., et al. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 23 (1994) 794-798
29. Hasdai D., Harrington R.A., Hochman J.S., et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 36 (2000) 685-692
30. Zeymer U., Tebbe U., Weber M., et al., on behalf of ALKK Study Group. Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial. J Invasive Cardiol 15 7 (2003) 385-389
31. Antoniucci D, Valenti R, Migliorini A, et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002;90(4):353-7.
32. Chan A.W., Chew D.P., Bhatt D.L., et al. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 89 2 (2002) 132-136
33. Hochman J.S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 107 (2003) 2998-3002
34. Cotter G., Kaluski E., Blatt A., et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 101 (2000) 1358-1361
35. Cotter G., Kaluski E., Milo O., et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 24 (2003) 1287-1295
36. Waknine Y. FDA approvals: orphan drugs troxatyl, tilarginine acetate, aerosolized gene therapy. Available at: http://www.medscape.com/viewarticle/507286. Accessed June 24, 2005.
37. Vakeva A.P., Agah A., Rollins S.A., et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97 (1998) 2259-2267
38. Fitch J.C., Rollins S., Matis L., et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100 (1999) 2499-2506
39. Granger C.B., Mahaffey K.W., Weaver W.D., et al. Pexelizumab. An anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108 (2003) 1184-1191
40. Hughes S. Apex AMI pexelizumab trial to be stopped early. Available at: www.theheart.org/article/640883.do. Accessed February 3, 2006.
41. Mahaffey K.W., Puma J.A., Barbagelata A., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol 34 (1999) 1711-1720
42. Théroux P., Chaitman B.R., Danchin N., et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation 102 (2000) 3032-3038
43. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial. J Am Coll Cardiol 38 (2001) 1644-1650
44. Flaherty J.T., Pitt B., Gruber J.W., et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty forAMI. Circulation 89 (1994) 1982-1991
45. Zhang Y., Patel A.A., Juergens C., et al. N-Acetylcysteine improves myocardial salvage after reperfusion therapy in humans. [abstract]. Circulation 100 Suppl I (1999) I-371
46. Diaz R., Paolasso E.A., Piegas L.S., et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98 (1998) 2227-2234
47. Mehta S.R., Yusuf S., Diaz R., et al. CREATE-ECLA Trial Group investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293 4 (2005) 437-446
48. Dunkman W.B., Leinbach R.C., Buckley M.J., et al. Clinical and hemodynamic results of intraaortic balloon pumping and surgery for cardiogenic shock. Circulation 46 (1972) 465-477
49. Subramanian V.A., Roberts A.J., Zema M.J., et al. Cardiogenic shock following acute myocardial infarction; late functional results after emergency cardiac surgery. N Y State J Med 80 6 (1980) 947-952
50. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341 (1999) 625-634
51. Duvernoy C.S., and Bates E.R. Management of cardiogenic shock attributable to acute myocardial infarction in the reperfusion era. J Intensive Care Med 20 (2005) 188-198
52. Lee L., Bates E.R., Pitt B., et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 78 (1988) 1345-1351
53. Lee L., Erbel R., Brown T.M., et al. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long term survival. J Am Coll Cardiol 17 (1991) 599-603
54. Verna E., Repetto S., Boscarini M., et al. Emergency coronary angioplasty in patients with severe left ventricular dysfunction or cardiogenic shock after acute myocardial infarction. Eur Heart J 10 (1989) 58-66
55. Disler L., Haitas B., Benjamin J., et al. Cardiogenic shock in evolving myocardial infarction: treatment by angioplasty and streptokinase. Heart Lung 16 (1987) 649-652
56. Berger P.B., Holmes Jr. D.R., Stebbins A.L., et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Aactivator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 96 (1997) 122-127
57. Urban P., Stauffer J.C., Bleed D., et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction: the (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 96 (1999) 1030-1038
58. Dzavik V., Sleeper L.A., Cocke T.P., et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK trial registry. Eur Heart J 24 (2003) 828-837
59. Dauerman H.L., Ryan Jr. T.J., Piper W.D., et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 15 (2003) 380-384
60. Webb J.G., Lowe A.M., Sanborn T.A., et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 42 (2003) 1380-1386
61. Sanborn T., Sleeper L., Webb J., et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 42 (2003) 1373-1379
62. Dauerman H.L., Goldberg R.J., White K., et al. Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 90 (2002) 838-842
63. Jacobs A.K., French J.K., Col J., et al. Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 36 3 Suppl A (2000) 1091-1096
64. Iakobishvili Z., Behar S., Boyko V., et al. Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines?. Am Heart J 149 1 (2005) 98-103
65. Rogers W.J., Canto J.G., Lambrew C.T., et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999:the national registry of myocardial infarction 1, 2 and 3. J Am Coll Cardiol 36 (2000) 2056-2066
66. Ohman M.E., Nannas J., and Stomel R.J. Thrombolysis and Counterpulsation to Improve Cardiogenic Shock Survival (TACTICS): results of a prospective randomized trial. [abstract]. Circulation 102(Suppl II) (2000) 600
67. French J.K., Miller D., Palmieri S., et al. Cardiogenic shock treated with thrombolytic therapy and intra-aortic balloon counter pulsation: a report from the SHOCK trial. [abstract]. Circulation 100 Suppl I (1999) I-370
68. Leshnower B.G., Gleason T.G., O'Hara M.L., et al. Safety and efficacy of left ventricular assist device support in postmyocardial infarction cardiogenic shock. Ann Thorac Surg 81 4 (2006) 1365-1370
69. Tayara W., Starling R.C., Yamani M.H., et al. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment. J Heart Lung Transplant 25 5 (2006) 504-509
70. James K.B., Militello M., Gus B., et al. Biventricular pacing for heart failure patients on inotropic support, a review of 38 consecutive cases. Tex Heart Inst J 33 1 (2006) 19-22
71. Konstantino Y., Iakobishvili Z., Arad O., et al. Urgent cardiac resynchronization therapy in patients with decompensated chronic heart failure receiving inotropic therapy. A case series. Cardiology 106 1 (2006) 59-62
72. Cowburn P.J., Patel H., Jolliffe R.E., et al. Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure?. Eur J Heart Fail 7 2 (2005) 215-217